The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 21, 2025

Filed:

Oct. 25, 2021
Applicant:

The Governors of the University of Alberta, Edmonton, CA;

Inventors:

Michael Houghton, Danville, CA (US);

Darren Hockman, Edmonton, CA;

John L. Law, Edmonton, CA;

Chao Chen, Edmonton, CA;

Michael Logan, Edmonton, CA;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/005 (2006.01); A61K 39/00 (2006.01); A61K 39/12 (2006.01); A61K 39/29 (2006.01); A61P 31/14 (2006.01); C07K 1/22 (2006.01); C07K 19/00 (2006.01); C12N 7/00 (2006.01); C12N 15/62 (2006.01); C12P 21/02 (2006.01);
U.S. Cl.
CPC ...
C07K 14/005 (2013.01); A61K 39/12 (2013.01); A61K 39/29 (2013.01); A61P 31/14 (2018.01); C07K 1/22 (2013.01); C07K 19/00 (2013.01); C12N 7/00 (2013.01); C12N 15/62 (2013.01); C12P 21/02 (2013.01); A61K 2039/54 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/55572 (2013.01); A61K 2039/575 (2013.01); C07K 2319/30 (2013.01); C07K 2319/50 (2013.01); C12N 2770/24222 (2013.01); C12N 2770/24234 (2013.01); C12N 2770/28122 (2013.01);
Abstract

The present disclosure provides affinity tagged heterodimeric polypeptides comprising a hepatitis C virus (HCV) E1 polypeptide and an HCV E2 polypeptide, where one or both of the E1 and E2 polypeptides comprises an affinity tag. The present disclosure provides a method of producing an affinity tagged E1/E2 heterodimer of the present disclosure. The present disclosure provides methods of producing untagged HCV E1/E2 heterodimers. The present disclosure provides HCV E1/E2 heterodimers, compositions comprising same, and methods of inducing an immune response to HCV.


Find Patent Forward Citations

Loading…